JP2023512648A5 - - Google Patents
Info
- Publication number
- JP2023512648A5 JP2023512648A5 JP2022545141A JP2022545141A JP2023512648A5 JP 2023512648 A5 JP2023512648 A5 JP 2023512648A5 JP 2022545141 A JP2022545141 A JP 2022545141A JP 2022545141 A JP2022545141 A JP 2022545141A JP 2023512648 A5 JP2023512648 A5 JP 2023512648A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025184688A JP2026026092A (ja) | 2020-01-27 | 2025-10-31 | コロナウイルスワクチン製剤 |
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062966271P | 2020-01-27 | 2020-01-27 | |
| US62/966,271 | 2020-01-27 | ||
| US202062976858P | 2020-02-14 | 2020-02-14 | |
| US62/976,858 | 2020-02-14 | ||
| US202062983180P | 2020-02-28 | 2020-02-28 | |
| US62/983,180 | 2020-02-28 | ||
| US202063048945P | 2020-07-07 | 2020-07-07 | |
| US63/048,945 | 2020-07-07 | ||
| US202063051706P | 2020-07-14 | 2020-07-14 | |
| US63/051,706 | 2020-07-14 | ||
| US202063054182P | 2020-07-20 | 2020-07-20 | |
| US63/054,182 | 2020-07-20 | ||
| US16/997,001 | 2020-08-19 | ||
| US16/997,001 US10953089B1 (en) | 2020-01-27 | 2020-08-19 | Coronavirus vaccine formulations |
| US202063129392P | 2020-12-22 | 2020-12-22 | |
| US63/129,392 | 2020-12-22 | ||
| PCT/US2021/015220 WO2021154812A1 (en) | 2020-01-27 | 2021-01-27 | Coronavirus vaccine formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025184688A Division JP2026026092A (ja) | 2020-01-27 | 2025-10-31 | コロナウイルスワクチン製剤 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023512648A JP2023512648A (ja) | 2023-03-28 |
| JP2023512648A5 true JP2023512648A5 (https=) | 2024-02-02 |
| JPWO2021154812A5 JPWO2021154812A5 (https=) | 2024-02-02 |
| JP7792339B2 JP7792339B2 (ja) | 2025-12-25 |
Family
ID=77079351
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022545141A Active JP7792339B2 (ja) | 2020-01-27 | 2021-01-27 | コロナウイルスワクチン製剤 |
| JP2025184688A Pending JP2026026092A (ja) | 2020-01-27 | 2025-10-31 | コロナウイルスワクチン製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025184688A Pending JP2026026092A (ja) | 2020-01-27 | 2025-10-31 | コロナウイルスワクチン製剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230070886A1 (https=) |
| EP (1) | EP4097123A4 (https=) |
| JP (2) | JP7792339B2 (https=) |
| KR (1) | KR20220141302A (https=) |
| CN (1) | CN115720581A (https=) |
| AU (1) | AU2021214064A1 (https=) |
| BR (1) | BR112022014830A2 (https=) |
| CA (1) | CA3165371A1 (https=) |
| GB (1) | GB2610070A (https=) |
| IL (1) | IL295142A (https=) |
| MX (1) | MX2022009167A (https=) |
| TW (1) | TW202142555A (https=) |
| WO (1) | WO2021154812A1 (https=) |
| ZA (1) | ZA202401922B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| EP3901261A1 (en) | 2020-04-22 | 2021-10-27 | BioNTech RNA Pharmaceuticals GmbH | Coronavirus vaccine |
| WO2021249116A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Coronavirus vaccine compositions, methods, and uses thereof |
| WO2021249011A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Hiv vaccine compositions, methods, and uses thereof |
| WO2022041760A1 (en) | 2020-08-31 | 2022-03-03 | Sichuan Clover Biopharmaceuticals, Inc. | Methods and compositions for purification of trimeric fusion proteins |
| WO2022235663A1 (en) * | 2021-05-05 | 2022-11-10 | Novavax, Inc. | Coronavirus and influenza compositions and methods for using them |
| CN113773372B (zh) * | 2021-08-15 | 2024-08-02 | 北京科兴中维生物技术有限公司 | 重组蛋白及其制备方法和应用 |
| CN116041448B (zh) * | 2021-08-26 | 2025-05-13 | 江苏瑞科生物技术股份有限公司 | 新型冠状病毒免疫原性物质、其制备方法和应用 |
| EP4436984A1 (en) * | 2021-11-24 | 2024-10-02 | Flagship Pioneering Innovations VI, LLC | Coronavirus immunogen compositions and their uses |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| KR20240125935A (ko) * | 2021-11-30 | 2024-08-20 | 노바백스, 인코포레이티드 | 코로나바이러스 백신 제형물 |
| CN114031675B (zh) * | 2022-01-10 | 2022-06-07 | 广州市锐博生物科技有限公司 | 基于SARS-CoV-2的S蛋白的疫苗和组合物 |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| EP4709741A1 (en) * | 2023-05-12 | 2026-03-18 | Icosavax, Inc. | Coronavirus spike glycoprotein receptor binding domains and uses thereof |
| US20250109187A1 (en) | 2023-09-28 | 2025-04-03 | Novavax, Inc. | ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1508615A1 (en) * | 2003-08-18 | 2005-02-23 | Amsterdam Institute of Viral Genomics B.V. | Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics |
| US20070124833A1 (en) * | 2005-05-10 | 2007-05-31 | Abad Mark S | Genes and uses for plant improvement |
| JP5813513B2 (ja) * | 2008-12-09 | 2015-11-17 | ノババックス，インコーポレイテッド | 修飾ｒｓｖｆタンパク質及びその使用方法 |
| US20130122032A1 (en) * | 2011-09-30 | 2013-05-16 | Gale Smith | Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus |
| KR102399854B1 (ko) * | 2013-09-19 | 2022-05-19 | 노바백스, 인코포레이티드 | 면역원성 중동호흡기증후군 코로나바이러스 (ΜＥＲＳ-ＣｏＶ) 조성물 및 방법 |
| EP4494650A3 (en) * | 2015-09-03 | 2025-03-26 | Novavax, Inc. | Vaccine compositions having improved stability and immunogenicity |
| US20170354729A1 (en) * | 2016-03-16 | 2017-12-14 | Novavax, Inc. | Vaccine compositions containing modified zika virus antigens |
| EP4599847A3 (en) * | 2016-10-25 | 2025-11-12 | Trustees of Dartmouth College | Prefusion coronavirus spike proteins and their use |
| MA47790A (fr) * | 2017-03-17 | 2021-05-05 | Modernatx Inc | Vaccins à base d'arn contre des maladies zoonotiques |
| CN111499692B (zh) * | 2020-06-16 | 2020-12-04 | 国家纳米科学中心 | 靶向新型冠状病毒covid-19的多肽及其应用 |
-
2021
- 2021-01-27 CA CA3165371A patent/CA3165371A1/en active Pending
- 2021-01-27 JP JP2022545141A patent/JP7792339B2/ja active Active
- 2021-01-27 GB GB2212336.8A patent/GB2610070A/en not_active Withdrawn
- 2021-01-27 KR KR1020227029337A patent/KR20220141302A/ko active Pending
- 2021-01-27 BR BR112022014830A patent/BR112022014830A2/pt unknown
- 2021-01-27 MX MX2022009167A patent/MX2022009167A/es unknown
- 2021-01-27 WO PCT/US2021/015220 patent/WO2021154812A1/en not_active Ceased
- 2021-01-27 EP EP21747453.5A patent/EP4097123A4/en active Pending
- 2021-01-27 TW TW110103013A patent/TW202142555A/zh unknown
- 2021-01-27 US US17/795,337 patent/US20230070886A1/en active Pending
- 2021-01-27 CN CN202180021579.8A patent/CN115720581A/zh active Pending
- 2021-01-27 IL IL295142A patent/IL295142A/en unknown
- 2021-01-27 AU AU2021214064A patent/AU2021214064A1/en active Pending
-
2024
- 2024-03-07 ZA ZA2024/01922A patent/ZA202401922B/en unknown
-
2025
- 2025-10-31 JP JP2025184688A patent/JP2026026092A/ja active Pending